Abstract 3911: Use of ALK inhibitors in patients with non-lung malignancies bearing <i>ALK</i> alteration prolongs treatment duration.
Vitor Góes(City of Hope), Sumanta Kumar Pal(City Of Hope National Medical Center), Vicki Doctor(Cancer Treatment Centers of America), Yu Jun Li(City of Hope), Charles B. Nguyen(City of Hope), Amber Moran(Cancer Treatment Centers of America), Joann Hsu(City of Hope), Koral Shah(City of Hope), Salvador Jaime-Casas(City of Hope), Jadon Cooper Fann(City of Hope), George Zhang(City of Hope), Alexander Chehrazi-Raffle(City of Hope), Daniela V. Castro(City of Hope), Miguel Zugman(City of Hope), Maurie Markman(Cancer Treatment Centers of America), Benjamin Mercier(City of Hope)
Cited by 0
Related Papers
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
|Cancer Immunology Research|2018|136
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.
|Journal of Clinical Oncology|2024|1